Yervoy — Total Revenues
Bristol-Myers Squibb Yervoy — Total Revenues decreased by 19.6% to $651M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.3%, from $624M to $651M. Over 4 years (FY 2021 to FY 2025), Yervoy — Total Revenues shows an upward trend with a 9.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market penetration and clinical demand for the therapy, while a decrease may signal increased competition from biosimilars or newer therapeutic alternatives.
Detailed definition
This metric represents the total global net sales generated by the Yervoy product line, a monoclonal antibody used in im...
Peer comparison
Comparable to revenue metrics for specific blockbuster oncology drugs or flagship therapeutic assets at other large-cap pharmaceutical companies.
bmy_segment_yervoy_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $510M | $515M | $545M | $515M | $525M | $523M | $568M | $508M | $585M | $579M | $566M | $583M | $630M | $642M | $675M | $624M | $728M | $739M | $810M | $651M |
| QoQ Change | — | +1.0% | +5.8% | -5.5% | +1.9% | -0.4% | +8.6% | -10.6% | +15.2% | -1.0% | -2.2% | +3.0% | +8.1% | +1.9% | +5.1% | -7.6% | +16.7% | +1.5% | +9.6% | -19.6% |
| YoY Change | — | — | — | — | +2.9% | +1.6% | +4.2% | -1.4% | +11.4% | +10.7% | -0.4% | +14.8% | +7.7% | +10.9% | +19.3% | +7.0% | +15.6% | +15.1% | +20.0% | +4.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's yervoy — total revenues?
- Bristol-Myers Squibb (BMY) reported yervoy — total revenues of $651M in Q1 2026.
- How has Bristol-Myers Squibb's yervoy — total revenues changed year-over-year?
- Bristol-Myers Squibb's yervoy — total revenues increased by 4.3% year-over-year, from $624M to $651M.
- What is the long-term trend for Bristol-Myers Squibb's yervoy — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's yervoy — total revenues has grown at a 9.4% compound annual growth rate (CAGR), from $2.03B to $2.9B.
- What does yervoy — total revenues mean?
- The total revenue generated from the sales of the Yervoy drug product.